UPLC-Q-TOF-MS combined with network pharmacology reveals effect and mechanism of Gentianella turkestanorum total extract in ameliorating non-alcoholic steatohepatitis.
10.19540/j.cnki.cjcmm.20250113.302
- Author:
Wu DAI
1
;
Dong-Xuan ZHENG
2
;
Ruo-Yu GENG
2
;
Li-Mei WEN
3
;
Bo-Wei JU
4
;
Qiang HOU
2
;
Ya-Li GUO
2
;
Xiang GAO
2
;
Jun-Ping HU
2
;
Jian-Hua YANG
3
Author Information
1. College of Pharmacy, Xinjiang Medical University Urumqi 830017, China Xinjiang Key Laboratory of Drug Clinical Research Urumqi 830011, China.
2. College of Pharmacy, Xinjiang Medical University Urumqi 830017, China.
3. Department of Pharmacy, the First Affiliated Hospital of Xinjiang Medical University Urumqi 830011, China Xinjiang Key Laboratory of Drug Clinical Research Urumqi 830011, China.
4. Xinjiang Key Laboratory of Drug Clinical Research Urumqi 830011, China the Fifth Affiliated Hospital of Xinjiang Medical University Urumqi 830011, China.
- Publication Type:Journal Article
- Keywords:
Gentianella turkestanorum total extract(GTI);
PI3K/AKT/NF-κB signaling pathway;
network pharmacology;
non-alcoholic steatohepatitis(NASH)
- MeSH:
Animals;
Non-alcoholic Fatty Liver Disease/genetics*;
Mice;
Network Pharmacology;
Male;
Drugs, Chinese Herbal/administration & dosage*;
Chromatography, High Pressure Liquid;
Liver/metabolism*;
Mice, Inbred C57BL;
Humans;
Mass Spectrometry;
Tumor Necrosis Factor-alpha/metabolism*;
Disease Models, Animal;
Molecular Docking Simulation
- From:
China Journal of Chinese Materia Medica
2025;50(7):1938-1948
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to reveal the effect and mechanism of Gentianella turkestanorum total extract(GTI) in ameliorating non-alcoholic steatohepatitis(NASH). UPLC-Q-TOF-MS was employed to identify the chemical components in GTI. SwissTarget-Prediction, GeneCards, OMIM, and TTD were utilized to screen the targets of GTI components and NASH. The common targets shared by GTI components and NASH were filtered through the STRING database and Cytoscape 3.9.0 to identify core targets, followed by GO and KEGG enrichment analysis. AutoDock was used for molecular docking of key components with core targets. A mouse model of NASH was established with a methionine-choline-deficient high-fat diet. A 4-week drug intervention was conducted, during which mouse weight was monitored, and the liver-to-brain ratio was measured at the end. Hematoxylin-eosin staining, Sirius red staining, and oil red O staining were employed to observe the pathological changes in the liver tissue. The levels of various biomarkers, including aspartate aminotransferase(AST), alanine aminotransferase(ALT), hydroxyproline(HYP), total cholesterol(TC), triglycerides(TG), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C), malondialdehyde(MDA), superoxide dismutase(SOD), and glutathione(GSH), in the serum and liver tissue were determined. RT-qPCR was conducted to measure the mRNA levels of interleukin 1β(IL-1β), interleukin 6(IL-6), tumor necrosis factor α(TNF-α), collagen type I α1 chain(COL1A1), and α-smooth muscle actin(α-SMA). Western blotting was conducted to determine the protein levels of IL-1β, IL-6, TNF-α, and potential drug targets identified through network pharmacology. UPLC-Q-TOF/MS identified 581 chemical components of GTI, and 534 targets of GTI and 1 157 targets of NASH were screened out. The topological analysis of the common targets shared by GTI and NASH identified core targets such as IL-1β, IL-6, protein kinase B(AKT), TNF, and peroxisome proliferator activated receptor gamma(PPARG). GO and KEGG analyses indicated that the ameliorating effect of GTI on NASH was related to inflammatory responses and the phosphoinositide 3-kinase(PI3K)/AKT pathway. The staining results demonstrated that GTI ameliorated hepatocyte vacuolation, swelling, ballooning, and lipid accumulation in NASH mice. Compared with the model group, high doses of GTI reduced the AST, ALT, HYP, TC, and TG levels(P<0.01) while increasing the HDL-C, SOD, and GSH levels(P<0.01). RT-qPCR results showed that GTI down-regulated the mRNA levels of IL-1β, IL-6, TNF-α, COL1A1, and α-SMA(P<0.01). Western blot results indicated that GTI down-regulated the protein levels of IL-1β, IL-6, TNF-α, phosphorylated PI3K(p-PI3K), phosphorylated AKT(p-AKT), phosphorylated inhibitor of nuclear factor kappa B alpha(p-IκBα), and nuclear factor kappa B(NF-κB)(P<0.01). In summary, GTI ameliorates inflammation, dyslipidemia, and oxidative stress associated with NASH by regulating the PI3K/AKT/NF-κB signaling pathway.
